We are live on ! Find out more
NPCE icon

Neuropace
NPCE

24 hedge funds and large institutions have $82M invested in Neuropace in 2023 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 9 increasing their positions, 3 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

217% more capital invested

Capital invested by funds: $25.9M → $82M (+$56.1M)

200% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 3

0.69% more ownership

Funds ownership: 69.71% → 70.4% (+0.69%)

0% more funds holding

Funds holding: 24 → 24 (0)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 3

Holders
24
Holders Change
–
Holders Change %
0%
% of All Funds
0.38%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
3
Increased
9
Reduced
3
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
KLC
Kent Lake Capital
Nevada
+$489K
2
Morgan Stanley
Morgan Stanley
New York
+$266K
3
SCM
Soleus Capital Management
Connecticut
+$229K
4
Fidelity Investments
Fidelity Investments
Massachusetts
+$165K
5
Millennium Management
Millennium Management
New York
+$152K

Top Sellers

Rank Fund Capital Flow
1
American Century Companies
American Century Companies
Missouri
-$108K
2
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
-$35.3K
3
NCM
Nantahala Capital Management
Connecticut
-$29.3K
4
TRCT
Tower Research Capital (TRC)
New York
-$18.9K
5
BlackRock
BlackRock
New York
-$7.95K
Name Holding Trade Value Shares
Change 		Change in
Stake
KL
1
KCK Ltd
Bermuda
$26.1M – – –
O
2
OrbiMed
New York
$18.6M – – –
SCM
3
Soleus Capital Management
Connecticut
$11.3M +$229K +59,711 +3%
Morgan Stanley
4
Morgan Stanley
New York
$10.5M +$266K +69,423 +3%
Fidelity Investments
5
Fidelity Investments
Massachusetts
$6.93M +$165K +43,005 +3%
Millennium Management
6
Millennium Management
New York
$3.4M +$152K +39,711 +6%
NCM
7
Nantahala Capital Management
Connecticut
$1.98M -$29.3K -7,657 -2%
Vanguard Group
8
Vanguard Group
Pennsylvania
$1.38M +$86.6K +22,619 +8%
KLC
9
Kent Lake Capital
Nevada
$592K +$489K +127,676 New
Geode Capital Management
10
Geode Capital Management
Massachusetts
$332K – – –
BCM
11
Bridgeway Capital Management
Texas
$240K +$76.6K +20,000 +63%
BlackRock
12
BlackRock
New York
$151K -$7.95K -2,076 -6%
SG Americas Securities
13
SG Americas Securities
New York
$118K +$97.2K +25,388 New
State Street
14
State Street
Massachusetts
$104K – – –
Northern Trust
15
Northern Trust
Illinois
$75K – – –
Renaissance Technologies
16
Renaissance Technologies
New York
$67K +$4.21K +1,100 +8%
Susquehanna International Group
17
Susquehanna International Group
Pennsylvania
$65.2K +$53.8K +14,052 New
Bank of America
18
Bank of America
North Carolina
$60.4K – – –
FAIM
19
Financial Advocates Investment Management
Washington
$46.4K – – –
UBS Group
20
UBS Group
Switzerland
$12.2K +$4.1K +1,071 +69%
TRCT
21
Tower Research Capital (TRC)
New York
$4K -$18.9K -4,928 -86%
BWM
22
BerganKDV Wealth Management
Minnesota
$1.95K – – –
Wells Fargo
23
Wells Fargo
California
$1.02K +$578 +151 +222%
Barclays
24
Barclays
United Kingdom
$548 – – –
American Century Companies
25
American Century Companies
Missouri
– -$108K -72,508 Closed
1
2

NPCE Hedge Fund Activity: Q1 2023 in Review

24 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Neuropace (NPCE) for Q1 2023, worth a combined $82M — up 217% from $25.9M a quarter earlier.

Fund positioning in NPCE was balanced in Q1 2023: 3 funds opened new positions, 3 closed out, 9 added to existing stakes and 3 trimmed.

The largest buyer was Kent Lake Capital, opening a new position worth an estimated $489K. The largest seller was American Century Companies, exiting entirely with an estimated $108K sold.

  • 24 institutional investors held Neuropace (NPCE) as of Q1 2023, unchanged from Q4 2022.
  • Funds reported $82M of Neuropace stock for Q1 2023, up 217% quarter-over-quarter.
  • 3 funds opened new Neuropace positions in Q1 2023 and 3 closed out, a net change of 0 holders.
  • The largest Neuropace buyer in Q1 2023 was Kent Lake Capital, an estimated $489K added.
  • The largest Neuropace seller in Q1 2023 was American Century Companies, an estimated $108K sold.

Based on aggregated 13F filings for Q1 2023.